ADARx (ADRX) CFO/CBO Ryan Fisk Receives Award of 170,692 Shares

What Happened
Ryan Fisk, Chief Financial Officer and Chief Business Officer of ADARx Pharmaceuticals, received a grant of 170,692 derivative shares (reported as acquired at $0.00) on 2026-09-24. The filing reports a $0.00 price for the award, so no cash was paid at grant; the transaction is an equity compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-24; Form 4 filed: 2026-09-28 (timely).
• Transaction type: A — Award/Grant (derivative securities) reported at $0.00.
• Shares/units granted: 170,692; reported aggregate value: $0.
• Shares owned after transaction: Not specified in the filing.
• Vesting (footnote): 1/4 vests on 2027-09-24; remaining shares vest in equal quarterly installments thereafter over a three‑year period, subject to continued service.
• No 10b5-1 plan, tax-withholding or cashless-sale details were reported in the excerpt.

Context
This is a time‑based compensation grant intended for retention/incentive and does not represent an immediate market purchase or sale. Such derivative awards become economically meaningful only as they vest; separate Form 4 filings would appear if shares are later exercised or sold.